Enhanced levels of non-enzymatic glycation and pentosidine crosslinking in spontaneous osteoarthritis progression  by Willett, T.L. et al.
Osteoarthritis and Cartilage 20 (2012) 736e744Enhanced levels of non-enzymatic glycation and pentosidine crosslinking in
spontaneous osteoarthritis progression
T.L. Willett yzxk*, R. Kandel xk{#, J.N.A. De Croos xk, N.C. Avery yy, M.D. Grynpas xk{#
yDivision of Orthopaedic Surgery, Department of Surgery, University of Toronto, Canada
zDivision of Orthopaedic Surgery, Department of Surgery, Mount Sinai Hospital, Toronto, Canada
x Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada
k Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
{ Laboratory Medicine and Pathobiology, University of Toronto, Canada
# Institute for Biomaterials and Biomedical Engineering, University of Toronto, Canada
yyMatrix Biology Group, Clinical Veterinary Sciences, University of Bristol, UKa r t i c l e i n f o
Article history:
Received 26 September 2011
Accepted 22 March 2012
Keywords:
Cartilage
Osteoarthritis
Advanced glycation endproducts
Ribation
Pentosidine* Address correspondence and reprint requests to:
Research Laboratory, Samuel Lunenfeld Research Insti
Orde Street, Room 417, Toronto, Ontario M5T 3H
4800x4491.
E-mail address: willett@lunenfeld.ca (T.L. Willett).
1063-4584/$ e see front matter  2012 Osteoarthriti
doi:10.1016/j.joca.2012.03.012s u m m a r y
Objective: To test the hypothesis that heightened advanced glycation endproducts (AGEs) content in
cartilage accelerates the progression of spontaneous osteoarthritis (OA) in the Hartley guinea pig (HGP)
model.
Methods: Twenty-eight male, 3-month-old HGPs were used. Eight were left untreated as a baseline
control group and sacriﬁced at 3 months of age (n ¼ 4) and 9 months of age (n ¼ 4; age-matched
controls). The other 20 HGPs received intra-articular knee injections in the right knee whereas the left
knees acted as contra-lateral non-injected controls. Injections consisted of 100 ml phosphate buffered
saline (PBS; n ¼ 10) or PBSþ2.0 M D-()-Ribose (n ¼ 10). Injections were given once weekly for 24 weeks.
At the end of the treatment period, the tibiae were ﬁxed with formalin, scanned with microCT for sub-
chondral bone mineral density, and then histological slides were prepared, stained with Safranin-O with
Fast Green counter stain and scored using the OARSI-HISTOgp scheme. Cartilage pentosidine (established
biomarker for AGEs) content, collagen content (% dry mass), glucosaminoglycan GAG-to-collagen ratio
(mg/mg), GAG-to-DNA ratio and DNA-to-collagen ratio were measured.
Results: Pentosidine content increased greatly due to PBS þ Ribose injection (P < 0.0001) and reached
levels found in cartilage from 80-year-old humans. Surprisingly, mean OARSI-HISTOgp scores for both
the injected and contra-lateral controls in the PBS þ Ribose group were not detectably different, nor were
they different from the mean score for the age-matched control group.
Conclusion: AGEs accumulation due to intra-articular ribose-containing injections in the HGP model of
spontaneous knee OA did not enhance disease progression.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The mechanisms of osteoarthritis (OA) continue to be sought
and clariﬁed. It has recently been proposed that biochemical
structures termed Advanced Glycation Endproducts (AGEs), which
play roles in ageing and diabetes, also play a role in the patho-
genesis of OA1.
OA is a slowly progressive disorder, characterized by destruction
of the cartilage, sclerosis of sub-chondral bone, formation of boneT.L. Willett, Musculoskeletal
tute, Mount Sinai Hospital, 25
7, Canada. Tel: 1-416-586-
s Research Society International. Pcysts, and the presence of osteophytes2. OA progression is thought
to start with articular surface ﬁbrillation, proceeding to eventual
full thickness loss3e5. OA is often categorized into two groups (a)
Primary idiopathic spontaneous OA and (b) Secondary OA caused
by mechanical trauma or joint instability6. Although much effort
has been put into studies of primary OA, little is known of its
aetiology and pathogenesis. Human primary OA prevalence and
severity is strongly correlated with an individuals age7. Interest-
ingly, it seems that other diseases can affect OA progression. For
examples, OA seems to onset earlier and more rapidly in obese
patients8 and patients with diabetes1,9.
AGEs are the result of non-enzymatic glycation (NEG); post-
translational modiﬁcation of proteins by reducing sugars and
reactive dicarbonyls that can subsequently form highly stable
covalent adducts and crosslinks between arginine and (hydroxy)ublished by Elsevier Ltd. All rights reserved.
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the major player but other reducing sugars and metabolites can do
the same at a faster rate10,12e18. AGEs negatively affect the physical
properties and cell interactions of collagen10,19,20 and glyco-
saminoglycans21e24 and also negatively affect cartilage metabolism
by slowing tissue turnover23. AGEs are only removed during tissue
catabolism and therefore in tissues with low turnover (cartilage
100þ years turnover period25) AGE accumulation can be signiﬁ-
cant. AGE accumulation in cartilage has been shown to increase
with age (after skeletal maturity)26 as growth and remodelling
slow. AGE levels are signiﬁcantly higher in the tissues of diabetic
patients due to hyperglycaemia27.
Recently, Verzijl et al. stated that “age-related accumulation of
AGEs in articular cartilage may provide a molecular mechanism
capable of (at least in part) explaining the age-related increase in
incidence of osteoarthritis”1. To date, a clear mechanistic link
between AGE accumulation and OA pathogenesis is lacking. One
possibility is a purely mechanical mechanism by which AGE accu-
mulation makes cartilage more susceptible to mechanical damage
through embrittlement of the matrix. However, it is more likely that
AGEs play a role by multiple mechanisms because AGE accumula-
tion makes the tissue more resistant to matrix metalloproteinases
and tissue metabolism and turnover are diminished21e23,28. There
also may be a role for AGE-RAGE (receptor for AGEs) mediated
signalling in chondrocytes29,30. Chondrocytes express RAGE and
RAGE signalling is thought to be pro-inﬂammatory and may play
a role in cartilage destruction29,30.
As a ﬁrst step, a clear causative link between AGE accumulation
and OA must be demonstrated in vivo. DeGroot et al.31 studied the
role of AGEs in a female beagle dog model of OA. AGE levels of the
right knee were increased 4-fold (from 0.1 to 0.4 mmol pentosidine
per mol collagen) by intra-articular ribose solution injections
compared to PBS controls. This was followed by anterior cruciate
ligament (ACL) transection, causing knee instability andmechanical
damage. Ribose followed by ACL transection resulted in a slightly
higher OA score compared to ACL transection after PBS injections.
While this was the ﬁrst in vivo evidence that AGEs may worsen OA,
the model was of secondary OA and the AGE accumulation and OA
progression were not concurrent, which differs from age-related
idiopathic OA. Additionally, the effect was small.
If AGEs meaningfully contribute to the pathogenesis of OA, one
might expect a large increase in disease severity given sufﬁcient AGE
content and time. To determine if AGEs accelerate OA progression,
this model should be evaluated in a spontaneous animal model of
primary OA.
Studies of primary OA progression in humans are difﬁcult
because of the slow disease progression, symptoms often present
only in late stages of disease, and a lack of biomarkers indicative of
disease progression32. Thus numerous animal models have been
developed but most are model secondary OA, using mechanical
insult or instability to drive the disease. Hartley guinea pigs (HGPs)
develop progressive, idiopathic arthropathy and males spontane-
ously develop OA due to rapid growth, weight gain3 and biome-
chanical factors such as meniscus calciﬁcation4,5. OA and obesity
are often concurrent in humans8,33. The medial compartments are
most affected and earliest changes (surface ﬁbrillation) are noted
around 2e3 months of age3,5. At 6 months of age, medial tibial OA
is moderate3,5. At 9 months, the OA is more severe and extends to
other regions of the cartilage3,5. The HGP is an established model
and is used for pathogenesis and therapeutic studies3,5 because
it mimics the changes found in human cartilage during OA
progression.
Our hypothesis was that increased levels of AGEs in the tissues
of the knee joint would meaningfully increase the progression of
spontaneous OA in the HGP model; given sufﬁcient time, the effectwould be quite large. We sought to induce high levels of pentosi-
dine, the established AGE biomarker, similar to those found in the
cartilage of aged humans.
Materials and methods
Animals and treatments
Twenty-eight male, 2-month-old HGPs were acquired from
Charles River Laboratories and housed at the Department of
Comparative Medicine, University of Toronto for 1 month. Eight of
the HGPs were left untreated to serve as a baseline control group
and were sacriﬁced at either 3 months of age (n ¼ 4; normal
cartilage) or 9 months of age (n¼ 4; moderate OA) for evaluation of
healthy HGP cartilage and disease progression respectively. The
remaining 20 HGPs received intra-articular knee injections in the
right knee of either 100 ml phosphate buffered saline (PBS; n ¼ 10)
or 100 ml PBSþ2.0 M D-()-Ribose (n ¼ 10)31 whereas the left knees
acted as non-injected contra-lateral controls. D-Ribose was chosen
instead of D-glucose because it is over 10 times more likely to exist
in its open-chain aldehyde form and therefore 10 times more
reactive than glucose34. Many studies have demonstrated that
ribose will form AGEs both in vitro and in vivo14,17,35e38 and has
been used in a beagle dog model of secondary OA31.
Data from pilot work allowed the design of a treatment regime
that would achieve levels of pentosidine found in aged human
cartilage over a 6-month period. Treatment started at 3 months of
age when pentosidine levels are very low and disease is minimal5.
It is known that at approximately 9 months of age, HGPs have
moderate/severe OA3,5. Using the chosen 6-month window
allowed a gradual accumulation of AGEs superimposed on the
known progression of OA and therefore an effect due to AGE
accumulation would be detected as a greater progression of the
disease.
The HGPs were housed in pairs as recommended by Kraus
et al.5e one receiving PBS injection and one receiving PBSþ Ribose
injection. Injections were given while each animal was anes-
thetised with isoﬂurane (5 L/min for less than 5 min) once weekly
for 24 weeks. The injections involved the insertion of an insulin
needle (29 gauge, 3/10cc Ultra-Fine insulin needle, Becton Dick-
inson, Mississauga, ON, Canada) into the joint space between the
tibia and femur. This involved an anterior approach, entering
lateral of the patellar tendon and distal of the patella. At the end of
the treatment period, the animals were humanely euthanized with
anaesthesia and T-61 injection. Our Animal Use Protocol was
approved by the University Animal Care Committee at the Univer-
sity of Toronto.
The sample size of 10 animals for the PBS and PBS þ Ribose
injected groups was chosen based on recommendations by Bend-
ele3 and becausewe expected that the effect of ribose injection over
the 6-month treatment period would be large if it were physio-
logically meaningful.
Specimen harvest
After euthanasia, the hind limbs were carefully dissected from
the carcass at the hip and placed in resealable plastic bags on ice.
Within the following 6 h, the limbs were kept on ice unless spec-
imens were being collected. The knees were disarticulated and
menisci were harvested and frozen for later use. The distal femora
were cut from the rest of femora and frozen in saline soaked gauze
until cartilage harvest for biochemistry (described below). The
tibiae were cut at the mid-diaphysis and the proximal specimen
was rinsed with PBS and immediately ﬁxed in 10% neutral buffered
formalin for 3 days.
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Once formalin ﬁxed, tibiae from the 9-month controls, PBS and
PBS þ Ribose groups were scanned with microCT (desktop 1174,
SkyScan, Belgium) to detect differences in sub-chondral bone
mineral density (BMD) in the medial plateau. Resolution was set to
17.5 mm voxel size and BMD was calibrated using phantoms of
known hydroxyapatite density embedded in epoxy. The microCT
scans were analyzed using SkyScan CTan software.
Histology and scoring
After ﬁxation and microCT scanning, the proximal tibiae were
decalciﬁed in 0.5 M Ethylenediaminetetraacetic acid (EDTA) for 2
weeks at room temperature. After the ﬁrst week, the tibial plateaus
were carefully cut into two halves on the coronal plane with a razor
blade using the ACL and tibial contra-lateral ligament as guides for
each cut. Then decalciﬁcation was continued for another week.
Decalciﬁcation was checked using radiography (Faxitron, Lincoln-
shire, IL, USA). Once decalciﬁed, the specimens were processed and
embedded in parafﬁn.
Five-mm thick sectionswere cut in the coronal plane at the centre
of the joint where maximum pathology occurs3,5. In the HGP, the
lateral tibial plateau is less affected by OA than the medial3,5.
Therefore, only the medial plateaus were scored. Sections were
stained using Safranin-O staining with Fast Green counter stain.
Scoring of the articular cartilage was conducted in a blinded and
randomized fashion using the OARSI-HISTOgp histo-chemical-
histological scoring system5. Two individuals (the ﬁrst author (TLW)
and a musculoskeletal pathologist (RK)) independently scored the
same section from each knee and the scores were averaged. The
scoring scheme included articular cartilage structure (score range:
0e8), proteoglycan content (score range: 0e6), cellularity (score
range: 0e3), tidemark integrity (score range: 0e1), and osteophytes
(score range: 0e3). The maximum possible total score was 215.
Cartilage pentosidine and collagen content
Cartilage was scraped from the patella-femoral groove of each
femur using a scalpel and then freeze-dried. Pentosidine and
hydroxyproline contents were measured following acid hydrolysis
in sealed glass vessels of the weighed, dry cartilage using hydro-
chloric acid for 24 h at 115C. The pentosidine assay utilized
a Dionex Ultimate 3000 autosampler (Dionex, Sunnyvale, CA, USA)
linked to a Dionex Ultimate 3000 pump and column compartment.
Chromatography was achieved using a 10 0.46 cm. Thermo
Electron Corporation Hypercarb column with an elution gradient
described elsewhere39. The column eluate was monitored using
a Dionex RF2000 ﬂuorescence detector set at 335 nm excitation and
385 nm emission, and the pentosidine quantiﬁed by comparison to
standard, supplied by Prof. Monnier (Cleveland, OH, USA), and
normalized to collagen content measured by a Burkard Scientiﬁc
autoanalyser (Middlesex, England) conﬁgured for hydroxyproline
determination. Data acquisition was via Dionex, CHROMELEON
software. Collagen content was normalized to dry weight to
provide a measure of collagen content.
Cartilage biochemistry
Cartilage was scraped from each medial condyle using a scalpel.
Tissue wet-weight was measured using an analytical balance and
lyophilized for 24 h. Dryweights ranged between 1.0mg and 2.0mg.
Subsequently, the cartilage was digested with papain (Sigma; 40 mg/
ml in 20 mM ammonium acetate, 1 mM EDTA, and 2 mM Dithio-
threitol) for 48 h at 65C and stored at 30C. Proteoglycan contentwas estimated by quantifying the amount of sulphated glycosami-
noglycans using the dimethylmethylene blue dye binding assay
(Polysciences Inc., Washington, PA) and spectrophotometry (wave-
length: 525 nm)40. A standard curve was generated using bovine
trachea chondroitin sulphate (Sigma). Collagen content was esti-
mated using hydroxyproline content41. Aliquots of the papain digest
were hydrolyzed in 6 N HCl at 110C for 18 h. Hydroxyproline
content was determined using chloramine-T/Ehlirch’s reaction and
spectrophotometry (wavelength: 561 nm) with L-hydroxyproline
(Sigma) as a standard. To determine the collagen content, it was
assumed that hydroxyproline comprises approximately 10% the
weight of collagen. DNA content was also determined using the
Hoechst dye 33258 assay (Polysciences Inc., Washington, PA) and
ﬂuorometry (emission wavelength: 458 nm and excitation wave-
length: 365 nm) with calf thymus DNA as the standard42.
Statistical analysis
Data are presented as mean  standard deviation. Statistical
analyses were conducted using SigmaStat v3.0 and SPSS v18 (SPSS,
Chicago, IL, USA) with P < 0.05 considered statistically signiﬁcant.
Normal distribution and equal variance were tested using the
KolmoroveSmirnov test and the Levene median test respectively.
Two-way analysis of variance (ANOVA) with one repeated factor
were used to detect effects due to injection, injection type and,
more importantly, an interaction between injection and injection
type in the 9-month PBS and PBS þ Ribose groups. Each injected
knee had a non-injected contra-lateral control. This allowed
repeated measures analysis in one-factor (non-injected control vs
injected knee) and the analysis of difference in effect between the
two injection types (PBS or PBS þ Ribose).
One-way ANOVAwas used when making comparisons between
age groups (i.e., 3-month controls, 9-month controls, 9-month
treated groups (PBS, PBS þ Ribose)) when the effects of injection
were not signiﬁcant. The HolmeSidak method was used for
multiple comparisons post-hoc. If normality or equal variance
failed, non-parametric ANOVA procedures on ranks with Dunn’s
Method multiple comparisons tests were used. Two-way repeated
measures ANOVA was used to test for differences in mean body
mass between the PBS and PBS þ Ribose groups over time (weekly
measurements). Linear regression and multiple linear regression
were used to investigate correlations between the OARSI-HISTOgp
score and other measured variables.
Results
Ribose injection resulted in greatly increased cartilage
pentosidine content
24-weeks of 2.0 M ribose injections increased pentosidine
content of the femoral cartilage to that of an 80-year-old
human28,31 (7.7  1.7 mmol pentosidine per mol collagen). This is
approximately 16 times higher (P< 0.0001) than levels found in the
contra-lateral control knees (0.47  0.03 mmols pentosidine per
mol collagen). See Fig. 1. A small statistically signiﬁcant increase in
pentosidine content with age was also observed between the
3-month controls and the 9-month-old controls (P < 0.001).
Lack of histological changes due to ribose injection
Two-way repeated measures ANOVA revealed that OARSI-
HISTOgp histological scores were not increased due to PBS þ
Ribose injection nor PBS injection compared to contra-lateral
control knees (injection type P ¼ 0.024; injection P ¼ 0.158; inter-
action P ¼ 0.256). The PBS group presented a higher mean score
Fig. 1. Mean pentosidine contents from the experimental groups and reference values from pilot work and the literature. Error bars represent one standard deviation. A great
increase in pentosidine content was measured in the PBS þ Ribose injected knees relative to all other groups (P < 0.0001). The value met the reference value for human cartilage
from an 80-year old28,31. Additionally, an expected and statistically detectable increase in pentosidine content was measured between 3 months of age and 9 months of age
(P < 0.001). The age-dependent increase is also seen in dog and human cartilage31. The value for HGP (Hartley guinea pig) meniscus represents the mean amount measured in our
pilot work using menisci from 1-year-old male retired breeders.
T.L. Willett et al. / Osteoarthritis and Cartilage 20 (2012) 736e744 739(by approximately three points) than the PBS þ Ribose group
(P ¼ 0.024; independent of injection), which had a score compa-
rable to the 9-month control group (8 points). See Fig. 2. Subse-
quent analysis conﬁrmed the expected increase in OARSI-HISTOgp
score with age. The 3-month controls had a lower score by
approximately four points (P < 0.01). Figure 3 presents example
histological sections from each of the groups.Fig. 2. OARSI-HISTOgp histological scores (mean  standard deviation) for the four e
(9 m) ¼ 9-month-old age-matched controls (n ¼ 4), PBS ¼ PBS injected group (n ¼ 10), PBS
injection (of either PBS or PBS þ Ribose; P ¼ 0.158) nor was an interaction detected (P ¼ 0.2
(P ¼ 0.0244) and the 9-month-old control group. * indicates that the mean score from theLack of evidence for an effect on cartilage biochemistry and
sub-chondral BMD due to ribose injection
Sub-chondral BMD and femoral cartilage collagen content data
did not present statistical evidence of effects due to injection
(P¼ 0.79 and 0.87 respectively) or injection type (P¼ 0.76 and 0.34
respectively). As expected, patella-femoral groove cartilage fromxperimental groups. Controls (3 m) ¼ 3-month-old controls (n ¼ 4). Controls
þ Ribose ¼ PBSþ2.0 M Ribose injected group (n ¼ 10). No effect was detected due to
36). The scores from the PBS injected group were higher than the PBS þ Ribose group
3-month control group was lower than the older groups (P < 0.01) as expected.
Fig. 3. Example histological sections (Safranin-O stained with Fast Green counter stain) from the controls and treatment groups. A ¼ 3-month-old controls, B ¼ 9-month-old
controls, C ¼ left contra-lateral control from PBS injected group, D ¼ right injected specimen from PBS injected group, E ¼ left contra-lateral control from PBS þ Ribose group,
F ¼ right injected specimen from PBS þ Ribose group.
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the 9-month groups (P < 0.001). GAG-to-Collagen ratio (GAG/Col),
GAG-to-DNA ratio (GAG/DNA) and Collagen-to-DNA ratio (Col/
DNA) data for the cartilage from the medial condyles did not
provide statistical evidence of an effect due to injection of
PBS þ Ribose. GAG/Col in the PBS and PBS þ Ribose groups was
lower than in the 9-month controls (P ¼ 0.029). Additionally, there
was a small but statistically detectable increase (P¼ 0.018) in GAG/
Col due to injection vs their contra-lateral controls and indepen-
dent of injection type (PBS vs PBS þ Ribose P ¼ 0.080). GAG/DNA
differed between the treatment groups (P < 0.001) but an effect
due to injection was not detected (P ¼ 0.80). GAG/DNA was lowest
in the 3-month controls and surprisingly low in the PBS þ Ribose
group. Col/DNA differed detectably between all groups but there
was a lack of statistical evidence for an effect due to injection
(P ¼ 0.48). The Col/DNA of 3-month-old controls was almost half
that of the other groups (P < 0.001). Unexpectedly, the PBS group
had higher Col/DNA than the PBSþ Ribose group and the 9-month-
old age-matched controls, which were not different statistically.
See Table I.Pentosidine content was not found to correlate with OARSI-
HISTOgp score (P > 0.05). Total histological score was found to
correlate positively with both Col/DNA (R2 ¼ 0.432, P < 0.001) and
with GAG/DNA (R2 ¼ 0.374, P < 0.001) but not GAG/Col (P ¼ 0.564).
Proteoglycan content score (data not shown) also correlated posi-
tively with GAG/DNA and negatively with GAG/Col in a multiple
linear regression model (R2 ¼ 0.396, P < 0.001).
Different growth rates between PBS and PBS þ Ribose
injected animals
The body mass of each animal in the PBS and PBS þ Ribose
groups was measured weekly and in the 9-month-old controls
group monthly. At time zero, there was no statistical evidence for
differences in mean body mass between the age-matched controls,
the PBS injected group and the PBS þ Ribose injected group
(P¼ 0.63). Interestingly, the body masses of the PBSþ Ribose group
increased at a slower rate as those of the PBS injected group. After
week 12 of the injections, there was a difference of on average
7% between the PBS injected and PBS þ Ribose injected animals
Table I
Sub-chondral BMD and biochemistry data for control and treatment groups
Controls (3 months) Controls (9 months) PBS injected PBS þ Ribose injected
Left Right Left Right Left Right Left Right
Sub-chondral vBMD (g/cm3) Not available Not available 0.890  0.019 0.851  0.038 0.878  0.015 0.900  0.041 0.894  0.040 0.872  0.032
% Collagen (wrt dry weight) 31.0  2.9* 31.3  4.16* 42.5  5.1 46.8  5.7 47.5  5.6 45.4  5.3 43.8  6.1 45.4  4.3
GAG/Col (ug/ug) 0.143  0.012 0.148  0.016 0.160  0.035 0.174  0.023 0.123  0.021y 0.128  0.016y,z 0.100  0.024y 0.123  0.020y,z
Col/DNA (ug/ug) 331  43 247  15 577x  55 576x  72 950k  150 890k  140 560x  110 550x  110
GAG/DNA (ug/ug) 47.5  7.5 36.4  2.4 91x  14 99.2x  4.4 117x  29 115x  27 56{  17# 67{  15#
* Detectably lower than the other groups (P < 0.001).
y Detectably lower than 9-month-old controls group (P ¼ 0.029).
z Detectably higher than contra-lateral controls (P ¼ 0.018).
x Detectably higher than the 3-month-old controls (P < 0.001).
k Detectably higher than all other groups (P < 0.001).
{ Detectably higher than the 3-month-old controls (P < 0.05).
# Detectably lower the PBS injected group (P < 0.001).
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P < 0.001, interaction P < 0.001)). See Fig. 4.
Discussion
In this in vivomodel of increased AGEs in spontaneous HGP OA,
worsening of the disease in terms of the histological hallmarks
quantiﬁed by the OARSI-HISTOgp score was not detected. Pento-
sidine concentration reached 7.7  1.7 mmol pentosidine per mol
collagen. This is comparable to that found in cartilage from 80-year-
old humans28,31 and is much higher than that measured in the
meniscal cartilage of aged guinea pigs and the articular cartilage of
dogs31.
The hypothesis for this study was that OA would be more
advanced in the guinea pig model due to heightened levels of AGEs
caused by ribose injections. Our hypothesis may be incorrect.
In vivo ribation and resulting AGEs may not be the correct model,
even with the high levels of pentosidine crosslinks formed. Some
studies suggest that cartilage becomesmore brittle andmore prone
to biomechanical injury due to AGE crosslink accumulation35,38.
Other studies have shown that tissuemetabolism is affected by AGE
accumulation21,28 and that chondrocytes have receptors for AGEs
(RAGE)29. RAGE signalling is thought to be pro-inﬂammatory and
pro-catabolic30. Therefore, there are plausible mechanisms by
which AGE accumulation may contribute to OA progression. Such
an effect has not been conﬁrmed in the present study. Abstracts
from the 2011 OARSI World Congress suggest that OA may not be
exacerbated in the ribose injection model43e45. One abstract
reported a negative correlation between histological score and
cartilage pentosidine content in the later stages of the disease45.Fig. 4. Body mass data (mean  standard deviation) for the three groups (age-matched
controls, PBS injected, PBS þ Ribose injected). The PBS þ Ribose group consistently
gained less mass than the PBS group.As expected, we observed moderate tibial plateau OA in the
contra-lateral control knees of the two treatment groups and the
non-intervention control group3,5. Histological score was slightly
increased in the PBS injected group compared to the PBS þ Ribose
injected group for unknown reasons. When the measures of carti-
lage composition are taken as awhole and the correlations with the
histological score are considered, the data suggest that this group
may have contained fewer cells (lower DNA content). Although
highly speculative, it is possible that the PBS þ Ribose group scored
lower than the PBS group due to some protective effect caused by
the ribose against some of the effects of injection. Both treatment
groups demonstrated increased GAG/Col in the injected knees
possibly as a reaction to injection. Unfortunately, we could not
normalize DNA, GAG and collagen contents to specimen dry mass
due to a technical mistake duringmeasurement of the drymass and
this makes clear interpretation of the biochemical data difﬁcult.
In future studies, immunohistochemical methods might enable
better observation of changes in cartilage biochemistry and matrix
protein degradation. For example, antibodies to pentosidine and
carboxymethyllysine are available46,47. Additionally, antibodies to
detect degraded type-II collagen in OA48 (in guinea pigs49) are
available.
We hypothesized that we would observe a more severe histo-
logical grade of OA in the PBS þ Ribose injected knees, compared to
their contra-lateral control knees, the PBS group (suggested by
DeGroot dog study31) and the no-intervention controls. The dog
study reported a minor two point increase in Mankin scoring in
their ACL-transsected ribose-injected group relative to contra-
lateral non-injected and non-transsected controls and a small one
point (50%) increase compared to PBS-injected ACL-transsected
knees31. Increased score was not detected in the current study. In
fact, the mean scores of the ribose injected knees, their contra-
lateral knees and the no-intervention age-matched controls were
essentially the same.
This current study differs from the previous dog study31 in some
important ways. In the dog study, the AGE forming injections were
administered over a shorter period and the accumulation of pen-
tosidine was signiﬁcantly lower (increased 4-fold reaching
0.4 mmol per mol collagen)31 than in the current study (7.7 mmol
per mol collagen). The previous study also used an injurious
biomechanical insult in the form of ACL transection to drive OA
progression. The ACL transection was administered after the
injections. Therefore, the AGEs were present before injury. This
does not model the usual sequence of events in human secondary
OA (ACL injury is most common in younger humans who should
have low AGE content) nor in the idiopathic spontaneous form
(gradual accumulation of AGEs and signs of OA concurrently with
ageing). The present model induced AGE accumulation over
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idiopathic spontaneous form, and resulted in high levels of
pentosidine.
AGE accumulation is, in part, time and tissue turnover rate
dependent.We show that pentosidine is present at low levels in the
cartilage of HGPs and the content increased with age between 3
months and 9 months. We determined in pilot work that the
pentosidine content of the menisci from 1-year-old male retired
breeders is higher (Fig. 1).
The question remains: Are AGE content and severity of OA
causatively linked or are they simply each independently corre-
lated with ageing? Heightened oxidative stress occurs in OA and
ageing and is required in the formation of some AGEs such as
pentosidine50e52. Therefore, pentosidine in diseased cartilage may
be a result of OA rather than a causative factor in the disease.
Various studies have shown that pentosidine and other AGEs
are present in higher concentrations in osteoarthritic human
cartilage30,46,47.
The present model may be confounded by the lower body
masses of the PBSþ Ribose group compared to the PBS and 9-month
groups. The reason for this body mass difference is unknown but
one reason may be loss of appetite due to pain. However, no indi-
cations of painwere observed.When bodymass was included in our
statistical models, it was not found to be a signiﬁcant factor in the
OARSI-HISTOgp score. An important feature of the design of these
experiments is that the contra-lateral control knees represent
internal controls and they conﬁrmed a lack of detectable effect due
to ribose injection.
Formation of AGEs using ribose does not completely model the
complex and heterogeneous AGE formationmechanisms that occur
spontaneously in vivo. While ribose is adept at forming pentosidine
and some other AGE products14,18, it may not form the appropriate
ligand(s) for RAGE. Recent studies have demonstrated that the non-
ﬂuorescent AGE crosslink glucosepane is approximately twenty
times more abundant than pentosidine in skin53. If glucosepane is
found in cartilage, it may be a more suitable target because, at such
levels, it could affect cellematrix interactions and the biomechan-
ical durability of cartilage. Unfortunately, ribose is not known to
form glucosepane; a hexose is required54. Finally, compared to the
time course of human OA (decades), this study was relatively short-
term. This may have limited our ability to observe the conse-
quences of high AGE crosslink content. On the other hand, the
6-month period used in this study spans a large portion of the
documented disease progression and lifespan of this small animal
model.
In conclusion, our model using the HGP model and intra-
articular ribose injections has demonstrated greatly increased
pentosidine content without an increase in disease severity
assessed using histological hallmarks and OARSI-HISTOgp scoring.
The relationships between AGEs, ageing and OA remain to be
clariﬁed and fully understood.
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